Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 7
1997 8
1998 3
1999 12
2000 12
2001 15
2002 19
2003 36
2004 32
2005 48
2006 40
2007 71
2008 36
2009 32
2010 35
2011 38
2012 27
2013 32
2014 33
2015 10
2016 24
2017 20
2018 14
2019 14
2020 16
2021 15
2022 12
2023 9
2024 10
2025 18
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

635 results

Results by year

Filters applied: . Clear all
Page 1
Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.
Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S, Hours-Zesiger P, Nickisch J, Sieder C, Hentschke C, Maier-Peuschel M. Reuter U, et al. Cephalalgia. 2022 Feb;42(2):108-118. doi: 10.1177/03331024211053571. Epub 2021 Nov 7. Cephalalgia. 2022. PMID: 34743579 Free PMC article. Clinical Trial.
Patients with 4 migraine days per month and naive to study drugs were randomly assigned (1:1) to either subcutaneous erenumab (70 or 140 mg/month) plus topiramate placebo (erenumab group) or oral topiramate at the individual dose with optimal efficacy (50-100 mg/da …
Patients with 4 migraine days per month and naive to study drugs were randomly assigned (1:1) to either subcutaneous erenumab (70 or 140 mg …
Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.
Morley KC, Kranzler HR, Luquin N, Jamshidi N, Adams C, Montebello M, Tremonti C, Dali G, Logge W, Baillie A, Teesson M, Trent R, Haber PS. Morley KC, et al. Am J Psychiatry. 2024 May 1;181(5):403-411. doi: 10.1176/appi.ajp.20230666. Am J Psychiatry. 2024. PMID: 38706338 Clinical Trial.
For the number of standard drinks per drinking day per week, there was a significant time-by-treatment interaction, which favored topiramate. There were significant time-by-treatment effects, with greater reductions observed with topiramate than naltrexone for BMI, …
For the number of standard drinks per drinking day per week, there was a significant time-by-treatment interaction, which favored topiram …
Acupuncture plus topiramate placebo versus topiramate plus sham acupuncture for the preventive treatment of chronic migraine: A single-blind, double-dummy, randomized controlled trial.
Liu L, Chen Q, Zhao L, Lyu T, Nie L, Miao Q, Liu Y, Zheng L, Fu F, Luo Y, Zeng C, Zhang C, Peng P, Zhang Y, Li B. Liu L, et al. Cephalalgia. 2024 Jun;44(6):3331024241261080. doi: 10.1177/03331024241261080. Cephalalgia. 2024. PMID: 38860524 Free article. Clinical Trial.
They were randomly assigned (1:1) to receive acupuncture (three sessions/week) plus topiramate placebo (acupuncture group) or topiramate (50-100 mg/day) plus sham acupuncture (topiramate group) over 12 weeks, with the primary outcome being the mean change in …
They were randomly assigned (1:1) to receive acupuncture (three sessions/week) plus topiramate placebo (acupuncture group) or topi …
The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.
Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR; SANAD Study group. Marson AG, et al. Lancet. 2007 Mar 24;369(9566):1016-26. doi: 10.1016/S0140-6736(07)60461-9. Lancet. 2007. PMID: 17382828 Free PMC article. Clinical Trial.
Patients were randomly assigned to valproate, lamotrigine, or topiramate between Jan 12, 1999, and Aug 31, 2004, and follow-up data were obtained up to Jan 13, 2006. ...But there was no significant difference between valproate and topiramate in either the analysis o …
Patients were randomly assigned to valproate, lamotrigine, or topiramate between Jan 12, 1999, and Aug 31, 2004, and follow-up data w …
Safety and Efficacy of Topiramate in Individuals With Cryptogenic Sensory Peripheral Neuropathy With Metabolic Syndrome: The TopCSPN Randomized Clinical Trial.
Smith AG, Singleton JR, Aperghis A, Coffey CS, Creigh P, Cudkowicz M, Conwit R, Ecklund D, Fedler JK, Gudjonsdottir A, Hauer P, Herrmann DN, Kearney M, Kissel J, Klingner E, Quick A, Revere C, Stino A; NeuroNEXT NN108 TopCSPN Study Team. Smith AG, et al. JAMA Neurol. 2023 Dec 1;80(12):1334-1343. doi: 10.1001/jamaneurol.2023.3711. JAMA Neurol. 2023. PMID: 37870862 Free PMC article. Clinical Trial.
RESULTS: A total of 211 individuals were screened, and 132 were randomly assigned to treatment groups: 66 in the topiramate group and 66 in the placebo group. Age and sex were similar between groups (topiramate: mean [SD] age, 61 (10) years; 38 male [58%]; placebo: …
RESULTS: A total of 211 individuals were screened, and 132 were randomly assigned to treatment groups: 66 in the topiramate group and …
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Gadde KM, et al. Lancet. 2011 Apr 16;377(9774):1341-52. doi: 10.1016/S0140-6736(11)60205-5. Epub 2011 Apr 8. Lancet. 2011. PMID: 21481449 Clinical Trial.
FINDINGS: Of 2487 patients, 994 were assigned to placebo, 498 to phentermine 7.5 mg plus topiramate 46.0 mg, and 995 to phentermine 15.0 mg plus topiramate 92.0 mg; 979, 488, and 981 patients, respectively, were analysed. At 56 weeks, change in bodyweight was -1.4 k …
FINDINGS: Of 2487 patients, 994 were assigned to placebo, 498 to phentermine 7.5 mg plus topiramate 46.0 mg, and 995 to phentermine 1 …
A Randomized Clinical Trial of Prolonged Exposure Therapy With and Without Topiramate for Comorbid PTSD and Alcohol Use Disorder.
Norman SB, Luciano MT, Panza KE, Davis BC, Lyons M, Martis B, Matthews SC, Angkaw AC, Haller M, Lacefield K, Brody AL, Schnurr PP, Batki SL, Simpson TL, Anthenelli RM. Norman SB, et al. Am J Psychiatry. 2025 May 1;182(5):452-462. doi: 10.1176/appi.ajp.20240470. Epub 2025 Mar 19. Am J Psychiatry. 2025. PMID: 40103353 Free PMC article. Clinical Trial.
Because effects of topiramate were not maintained at longer-term follow-up, extending time on topiramate or additional strategies to prolong such effects may be useful. Topiramate did not show added benefit to PE for percent heavy drinking days or secondary o …
Because effects of topiramate were not maintained at longer-term follow-up, extending time on topiramate or additional strateg …
A randomized sequential cross-over trial evaluating five purportedly ICP-lowering drugs in idiopathic intracranial hypertension.
Mitchell JL, Lyons HS, Walker JK, Yiangou A, Thaller M, Grech O, Alimajstorovic Z, Tsermoulas G, Brock K, Mollan SP, Sinclair AJ. Mitchell JL, et al. Headache. 2025 Feb;65(2):258-268. doi: 10.1111/head.14897. Epub 2025 Jan 24. Headache. 2025. PMID: 39853738 Free PMC article. Clinical Trial.
After treatment, there was a further significant reduction in the fluid cognition domain (ability to process and integrate) with acetazolamide (mean T-score [SE]), -5.0 (2.6), p = 0.057 and topiramate -4.1 (2.0), p = 0.061. CONCLUSIONS: Acetazolamide, furosemide, spironola …
After treatment, there was a further significant reduction in the fluid cognition domain (ability to process and integrate) with acetazolami …
Optimal Dosing of Nortriptyline-Topiramate and Verapamil-Paroxetine Combinations in Tinnitus Treatment.
Lee EJ, Tawk K, Gutiérrez Pérez ML, Tsang C, Abouzari M, Djalilian HR. Lee EJ, et al. Laryngoscope. 2025 Nov;135(11):4348-4354. doi: 10.1002/lary.32338. Epub 2025 Jun 14. Laryngoscope. 2025. PMID: 40515518 Free PMC article. Clinical Trial.
OBJECTIVE: To determine effective dose strategies for nortriptyline-topiramate (NT) and verapamil-paroxetine (VP) combinations for tinnitus treatment. METHODS: This secondary analysis examined data from an 8-week, randomized, double-blind, placebo-controlled trial (RCT) ev …
OBJECTIVE: To determine effective dose strategies for nortriptyline-topiramate (NT) and verapamil-paroxetine (VP) combinations for ti …
Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine.
Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Hershey AD; CHAMP Investigators. Powers SW, et al. N Engl J Med. 2017 Jan 12;376(2):115-124. doi: 10.1056/NEJMoa1610384. Epub 2016 Oct 27. N Engl J Med. 2017. PMID: 27788026 Free PMC article. Clinical Trial.
There were no significant between-group differences in the primary outcome, which occurred in 52% of the patients in the amitriptyline group, 55% of those in the topiramate group, and 61% of those in the placebo group (amitriptyline vs. placebo, P=0.26; topiramate v …
There were no significant between-group differences in the primary outcome, which occurred in 52% of the patients in the amitriptyline group …
635 results